Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 5 Post-MI treatment in RA and control patients: comparison of three time periods

From: Rheumatoid arthritis patients receive less frequent acute reperfusion and secondary prevention therapy after myocardial infarction compared with the general population

  Prior to 1999 1999 to 2002 inclusive 2003 onward
Acute reperfusion (all patients)    
   RA patients, n (%) 6/16 (38%) 4/38 (10%)* 4/28 (12%)
   Controls, n (%) 10/19 (53%) 17/41 (41%) 6/30 (20%)
Acute reperfusion (STEMI patients)    
   RA patients, n (%) 6/10 (60%) 4/13 (31%)* 4/6 (67%)
   Controls, n (%) 9/12 (75%) 14/20 (70%) 6/7 (86%)
Thrombolysis    
   RA patients, n (%) 3/16 (19%) 3/42 (7%)* 2/32 (6%)
   Controls, n (%) 8/19 (42%) 12/41 (29%) 2/30 (7%)
Percutaneous coronary intervention    
   RA patients, n (%) 4/16 (25%) 3/42 (7%)* 3/32 (9%)*
   Controls, n (%) 3/19 (16%) 15/41 (36%) 12/30 (40%)
Aspirin    
   RA patients, n (%) 14/16 (88%) 41/42 (98%) 30/32 (94%)
   Controls, n (%) 19/19 (100%) 41/41 (100%) 29/30 (97%)
Beta blockers    
   RA patients, n (%) 8/16 (50%) 32/42 (76%) 24/32 (75%)
   Controls, n (%) 15/19 (79%) 32/41 (78%) 28/30 (93%)
ACE inhibitors    
   RA patients, n (%) 8/16 (50%) 29/42 (69%) 24/32 (75%)
   Controls, n (%) 14/19 (74%) 24/41 (58%) 19/30 (63%)
Lipid-lowering agents    
   RA patients, n (%) 0/16 (0)* 16/42 (38%)* 20/32 (62%)
   Controls, n (%) 7/19 (37%) 31/41 (76%) 25/30 (83%)
  1. ACE, angiotensin-converting enzyme; MI, myocardial infarction; RA, rheumatoid arthritis; STEMI, ST-elevation myocardial infarction. *P < 0.05 for the comparison with control patients.